|Articles|October 2, 2005

Pharmaceutical Technology

  • Pharmaceutical Technology-10-02-2005
  • Volume 29
  • Issue 10

Preserved in Translation

Author(s)Laura Bush

The translator strives for quality, for a flawless re-setting of ideas from language to language. It is precise, painstaking work, making sure that all the concepts are there, that the grammar and syntax are correct, that the register (the formality, the emotional and social tone) is accurate, and that the text reads smoothly.

The translator strives for quality, for a flawless re-setting of ideas from language to language. It is precise, painstaking work, making sure that all the concepts are there, that the grammar and syntax are correct, that the register (the formality, the emotional and social tone) is accurate, and that the text reads smoothly.

Laura Bush

Translated literature, from the Bible to García Márquez, moves individual hearts and molds whole societies. Reading a translation, though, most of us think only of the product, and forget the process that brought it to us. Only in recent decades has academia deemed translation worthy of study. Even today, translating (in writing) and interpreting (in speech) are still somehow second-class pursuits (witness hospitals that ask the janitor to interpret in the emergency room).

Yet growing numbers of people now realize the importance of understanding the key steps of translation: analyzing the original, transferring the concepts to the other culture, and restructuring them to fit the framework of another language. The translator asks many questions: Does this point hinge on culturally bound concepts that readers from other cultures won't immediately grasp? Was that metaphor an everyday expression in the source language, or a creative invention of the writer?

Pharmaceutical industry professionals go through their own translation steps, as they transfer formulations into manufacturing processes, ultimately converting scientific concepts and raw materials into finished products. Yet pharmaceutical manufacturing, like translation, has long suffered secondary status. Pharma manufacturing, too, has focused on the final product, not the process that produced it.

Today, however, all this is changing. Manufacturing scientists are shifting focus and FDA regulators are modifying rules to embrace dynamic models, trying to understand what the process does, not just what it produces.

And like translators, the pharmaceutical industry and the regulators are discovering that quality is the journey, not the destination.

Laura Bush is the managing editor of Pharmaceutical Technology, lbush@advanstar.com She is certified by the American Translators Association as a Spanish-to-English translator.

Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.